- Mesoblast (OTCPK:MEOBF) reported US$21.9M in gross revenue for the quarter ended September 30, 2025.
- This marks a 66% increase compared to the previous quarter.
- Growth driven by strong sales of Ryoncil (remestemcel-L-rknd).
- Ryoncil is the first FDA-approved mesenchymal stromal cell therapy. It remains the only approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
- Source: Press release
Mesoblast reports Q2 revenue surge of 66% on strong Ryoncil sales(Pink Current Info:MEOBF)
By Press Room
